VITRAKVI 25 MG Oral Capsule
- RxCUI
- 2105657
- RxNorm name
- VITRAKVI 25 MG Oral Capsule
- Display name
- VITRAKVI 25 MG Oral Capsule
- Full name
- VITRAKVI 25 MG Oral Capsule
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:47
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VITRAKVI | LAROTRECTINIB | Bayer HealthCare Pharmaceuticals Inc. | 0c8ca614-58b2-4aa4-83d3-0387a8f782fd | 2026-05-22 | Warnings, Adverse reactions | 2105657 |
| VITRAKVI | LAROTRECTINIB | Loxo Oncology, Inc. | 9525f887-a055-4e33-8e92-898d42828cd1 | 2018-12-05 | Warnings, Adverse reactions | 2105657 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 0c8ca614-58b2-4aa4-83d3-0387a8f782fd | Vitrakvi 25 MG Oral Capsule | SY | 21 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20260522 |
| 0c8ca614-58b2-4aa4-83d3-0387a8f782fd | Vitrakvi 25 MG (as 30.7 MG larotrectinib sulfate) Oral Capsule | SY | 21 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20260522 |
| 0c8ca614-58b2-4aa4-83d3-0387a8f782fd | larotrectinib 25 MG Oral Capsule [Vitrakvi] | SBD | 21 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20260522 |
| 0c8ca614-58b2-4aa4-83d3-0387a8f782fd | VITRAKVI 25 MG Oral Capsule | PSN | 21 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20260522 |
| 9525f887-a055-4e33-8e92-898d42828cd1 | VITRAKVI 25 MG Oral Capsule | PSN | 3 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20181205 |
| 9525f887-a055-4e33-8e92-898d42828cd1 | Vitrakvi 25 MG (as 30.7 MG larotrectinib sulfate) Oral Capsule | SY | 3 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20181205 |
| 9525f887-a055-4e33-8e92-898d42828cd1 | larotrectinib 25 MG Oral Capsule [Vitrakvi] | SBD | 3 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20181205 |
| 9525f887-a055-4e33-8e92-898d42828cd1 | Vitrakvi 25 MG Oral Capsule | SY | 3 | These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. VITRAKVI ® (larotrectinib) capsules, for oral use VITRAKVI ® (larotrectinib) oral solution Initial U.S. Approval: 2018 | 20181205 |